Who: Adamis Pharmaceuticals/DMK Pharmaceuticals
What: Publicly traded Adamis and privately held DMK will merge into a newly named public company focused on developing the...
Troubled Adamis To Merge With Private DMK, Focus On Neurological Disease
Deal Snapshot: Following a clinical failure for its COVID-19 candidate, Adamis sought strategic alternatives. DMK boasts a library of 750 first-in-class small molecule peptide analogues.
More from Deals
• By
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
More from Business
• By
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
• By
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.